Cellular Biomedicine Group Saving Life, Revitalizing Life
WWW.CELLBIOMEDGROUP.COM
Company Highlight
e ent Mile tone hie ed
C-CAR011 Ongoing Clinical Trials
MANAGEMENT
NASDAQ-listed China biopharmaceutical company focused on
immuno-oncology
and degene ati e di ea e hina a la ge ma ket population M ne an
e patient annually plu M nee teoa th iti patient
leading iopha ma euti al inno ato de eloping p op ieta y on t u
t and allogenei tem ell the apie utting edge and M a ilitie .ea
oned management team ith ienti i egulato y and inan ial e pe ti
e
Laun hed multi ente lini al t ial in L L & NHL Laun hed LL
lini al t ial in dult LL
u e ully ompleted ha e autologou t ial epo ted a e and p omi ing
ha e allogenei t ial
70,000 t in th ee hine e itie apa le o t eating an e patient pe
yea apa le o t eating patient pe yea tem ell
- Joint innovation laboratories with GE Healthcare and
ThermoFisher Scientific
Q M ela a e
Indicies: Broad-market Russell 3000® Index, small-cap Russell
2000® Index, Loncar China BioPharma index
Bizuo (Tony) LiuCEO, Executive Director Alibaba Group,
Microsoft
Yihong Yao, PhDCSOAstraZeneca, Abbvie, MedImmune
Helen Zhang Chief Production OfficerHarvard Medical School,
MDC
GM, Stem Cell Business UnitMedgene L ene al Ho pital
SVP, Legal, Corporate Development & Board Secretary
llied ignal a emi ondu to
GM, Early Diagnosis & Intervention
ioMe ieu an gene
JiaQiang Ren, PhDSr. Director, QA/ControlNIH
N te en eek l d
uite upe tino
+
in o ell iomedg oup om
Copyright Cellular Biomedicine Group, Inc. August 2018
Grace HeVP, Clinical Development
WWW.CELLBIOMEDGROUP.COM
mmuno n ology ipeline u ent tatu
tate o the t and M a ilitie
nteg ated M o ell he apy
RECENT M L HM N
otal M a ility 70,000 sq ft22 independent production lines53
clean rooms
ei ing
u i
hanghai
t ategi olla o ation ith GE Healthcare Life Sciences China to e
ta li h oint te hnology la o ato y
pp o al o ial in Non Hodgkin Lymphoma NHL in hina
- Opened new Shanghai GMP facility of 40,000 sq ft, to become
one of the largest in-house CAR-T manufacturers amongst leading
global biopharmaceutical companies
- Signed Strategic Partnership to Develop Manufacturing
Processes with Thermo Fisher Scientific
- Signed plan to configure part of CBMG facility in Shanghai
with GE Healthcare’s FlexFactory™ platform, designed to speed up
manufacturing timelines for cell therapy clinical trials and
commercial launch
la mid Manu a tu e i u Manu a tu e L
Manu a tu e L Manu a tu e L
hM Manu a tu e e ting ent e
ey eagent p epa ation
M g ade High apa ity g lotLo endoto in
mg High t an e tion ate
M g adet ong apa ity
Lentin et o dutomated pu i i ation
p o eHigh tite u ml
tanda di ation ent ali ed utomation lo ed y tem e um ee
High po iti e ate
High yield e High ia ility
lini g ade o en p odu t
LL = a ute lympho la ti leukemia L L = di u e la ge ell
lymphoma
ML = a ute myeloid leukemia HCC = hepatocellular carcinoma
MM = Multiple Myeloma
NHL = Non Hodgkin lymphoma NSCLC = NSCLC = Non small cell lung
cancer
Copyright Cellular Biomedicine Group, Inc. August 2018
Cellular Biomedicine Group Saving Life, Revitalizing Life
Opened R&D Center in Maryland, USA
